Featured Research

from universities, journals, and other organizations

New way to 'rescue' treatment sensitivity of breast cancer cells

Date:
May 13, 2010
Source:
Georgetown University Medical Center
Summary:
Researchers have identified a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant in estrogen receptor-positive breast cancers.

A study by researchers from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) identifies a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant in estrogen receptor-positive breast cancers.

Related Articles


The findings are published as the cover story of the May 15, 2010 issue of Molecular Cancer Therapeutics.

Fulvestrant is a common second-line therapy for women whose cancer progresses following anti-estrogen therapy. In this paper, Lombardi researchers identify a cytokine, a small protein called IFNγ, which appears to increase or even rescue sensitivity to fulvestrant.

Led by Robert Clarke, PhD, DSc, professor of oncology and physiology & biophysics at Lombardi, the research team identified a key downstream regulator of sensitivity to fulvestrant -- the protein IRF1. When cells were treated with both fulvestrant and IFNγ, Clarke and colleagues saw an increase in expression of IRF1, which resulted in increased apoptosis -- or programmed cell death -- of the cancer cells.

The American Cancer Society estimates that in 2009, 192,000 women were diagnosed with invasive breast cancer, and approximately 70 percent of these cases were considered to be estrogen receptor-positive (ER+), meaning that estrogen and its receptor drive the disease. While a number of anti-estrogen therapies are able to successfully treat these cancers, resistance may develop, often leading to disease progression.

"This finding is significant because we and others in the field have been searching for a long time for clinically relevant ways to make anti-estrogen therapies more effective for women with ER+ breast cancer," says Rebecca Riggins, PhD, assistant professor of oncology at Lombardi and co-author of the paper.

Most of the genes and proteins regulated by the estrogen receptor are unknown, and the molecular effects of therapies such as anti-hormonal drugs are also largely unidentified, says Clarke, who also serves as interim director of GUMC's Biomedical Graduate Research Organization.

However, in this paper, the research team has identified that the induction of IRF1 expression involves regulation of well-known cell fate proteins including NF-κB and the BCL-2 family of proteins, leading to apoptotic pathways. Ultimately, Clarke and colleagues suggest that a combination of anti-estrogens and compounds that up-regulate IRF1 expression -- like IFNγ -- may be useful for the treatment of anti-estrogen resistant ER+ breast cancers.

Clarke was also recently awarded a major program grant by the National Cancer Institute to lead a Center for Cancer Systems Biology addressing estrogen receptor signaling in breast cancer resistance.

In addition to Clarke and Riggins, authors include Yanxia Ning, Shanghai Medical College, Fudan University, Shanghai, P.R. China; Jennifer Mulla, Lombardi Comprehensive Cancer Center, Georgetown University; Haniee Chung, Lombardi Comprehensive Cancer Center, Georgetown University; and Alan Zwart, Lombardi Comprehensive Cancer Center, Georgetown University.


Story Source:

The above story is based on materials provided by Georgetown University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yanxia Ning, Rebecca B. Riggins, Jennifer E. Mulla, Haniee Chung, Alan Zwart, and Robert Clarke. IFNγ Restores Breast Cancer Sensitivity to Fulvestrant by Regulating STAT1, IFN Regulatory Factor 1, NF-κB, BCL2 Family Members, and Signaling to Caspase-Dependent Apoptosis. Molecular Cancer Therapeutics, 2010; 9: 1274-1285 DOI: 10.1158/1535-7163.MCT-09-1169

Cite This Page:

Georgetown University Medical Center. "New way to 'rescue' treatment sensitivity of breast cancer cells." ScienceDaily. ScienceDaily, 13 May 2010. <www.sciencedaily.com/releases/2010/05/100510092006.htm>.
Georgetown University Medical Center. (2010, May 13). New way to 'rescue' treatment sensitivity of breast cancer cells. ScienceDaily. Retrieved April 1, 2015 from www.sciencedaily.com/releases/2010/05/100510092006.htm
Georgetown University Medical Center. "New way to 'rescue' treatment sensitivity of breast cancer cells." ScienceDaily. www.sciencedaily.com/releases/2010/05/100510092006.htm (accessed April 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, April 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) — Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com
Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins